1 / 4

Mucormycosis: A Retrospective Study on Epidemiology and Risk Factors

This study conducted between 2005-2007 analyzes 101 cases of mucormycosis declared through the PMSI. 60 cases were proven and 41 were probable. The study focuses on demographics, underlying conditions, and factors contributing to the infection. The results highlight the emergence of this infection and its specificities based on location and underlying pathologies.

nuncio
Télécharger la présentation

Mucormycosis: A Retrospective Study on Epidemiology and Risk Factors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EORTC : European Organisation for Research and Treatment of Cancer Lanternier F et al. Clin Infect Dis 2012;54(Suppl.1):S35-43 • Étude rétrospective 2005-2007 (3 ans) • Cas déclarés par • PMSI (Programme de médicalisation des systèmes d’information) • CNRMA (Centre national de référence des mycoses et des antifongiques • 101 cas de mucormycose • 60 prouvés et 41 probables (EORTC) • 58 % d’hommes, âge moyen de 50,7 ans ± 19,9 • Facteurs favorisants • 50 % hémopathies (médiane : 8,8 mois après diagnostic hématologique) • 23 % diabète • 18 % traumatisme

  2. Lanternier F et al. Clin Infect Dis 2012;54(Suppl.1):S35-43 Résultats (1)

  3. Résultats (2) Lanternier F et al. Clin Infect Dis 2012;54(Suppl.1):S35-43

  4. AmB =amphotéricineB ; L-AmB = AmBliposomale ; AmB-lc : complexe lipidique d’AmB Lanternier F et al. Clin Infect Dis 2012;54(Suppl.1):S35-43 • Conclusion : infection émergente, spécificités selon la localisation et la pathologie sous-jacente

More Related